Overview

CKM For Safe Use of SGLT2i in Type 1 Diabetes

Status:
NOT_YET_RECRUITING

Trial end date:
2030-12-31

Target enrollment:

Participant gender:

Summary

This research study is being conducted to learn if wearing a combination continuous glucose monitor/continuous ketone monitor (CGM/CKM) can reduce the side effects of taking sotagliflozin (study drug) in people with type 1 diabetes.

Phase:

PHASE3

Details

Lead Sponsor:

University of California, San Diego

Collaborators:

Abbott
Lexicon Pharmaceuticals
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institutes of Health (NIH)

Treatments:

(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol